Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and …

MP Deek, K Van der Eecken, P Sutera… - Journal of clinical …, 2022 - ascopubs.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Defining oligometastatic disease in the new era of PSMA-PET imaging for primary staging of prostate cancer

SJ Galgano, AM McDonald, JT West, S Rais-Bahrami - Cancers, 2022 - mdpi.com
Simple Summary Oligometastatic prostate cancer has classically been defined as a small
volume of prostate cancer spread as defined by imaging using CT, MRI, and bone scans …

Impact of psma pet on prostate cancer management

AB Weiner, R Agrawal, LF Valle, I Sonni… - … treatment options in …, 2024 - Springer
Opinion statement PSMA-PET has been a practice-changing imaging biomarker for the
management of men with PCa. Research suggests improved accuracy over conventional …

Why bother with alpha particles?

AP King, FI Lin, FE Escorcia - European Journal of Nuclear Medicine and …, 2021 - Springer
The approval of 223 RaCl 2 for cancer therapy in 2013 has heralded a resurgence of
interest in the development of α-particle emitting radiopharmaceuticals. In the last decade …

Oligometastatic prostate cancer: current status and future challenges

H Jadvar, AL Abreu, LK Ballas… - Journal of Nuclear …, 2022 - Soc Nuclear Med
In accordance with the spectrum theory of metastatic disease, an oligometastatic clinical
state has been proposed as an intermediary step along the natural history of cancer with few …

[HTML][HTML] Patterns of recurrence and modes of progression after metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer

MP Deek, K Taparra, D Dao, L Chan, R Phillips… - International Journal of …, 2021 - Elsevier
Purpose Metastasis-directed therapy (MDT) is increasingly used in castration-sensitive
oligometastatic prostate cancer because it prolongs progression-free survival (PFS) and …

Combining external beam radiation and radionuclide therapies: Rationale, radiobiology, results and roadblocks

EM Abbott, N Falzone, N Lenzo, KA Vallis - Clinical Oncology, 2021 - Elsevier
The emergence of effective radionuclide therapeutics, such as radium-223 dichloride,[177
Lu] Lu-DOTA-TATE and [177 Lu] Lu-PSMA ligands, over the last 10 years is driving a rapid …

[HTML][HTML] Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy …

RC Winter, M Amghar, AS Wacker, G Bakos… - …, 2024 - pmc.ncbi.nlm.nih.gov
Cancer is one of the most complex and challenging human diseases, with rising incidences
and cancer-related deaths despite improved diagnosis and personalized treatment options …

Role of 18F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative …

B Savir-Baruch, PL Choyke, SP Rowe… - American Journal of …, 2021 - Am Roentgen Ray Soc
Twenty-five years ago, oligometastatic disease was proposed as an intermediary clinical
state of cancer with unique implications for therapies that may impact cancer evolution and …

Single-Fraction Stereotactic Ablative Body Radiotherapy for Primary and Extracranial Oligometastatic Cancers

H Greenwood, J Hassan, K Fife, TV Ajithkumar… - Clinical Oncology, 2023 - Elsevier
Stereotactic ablative body radiotherapy (SABR) consists of delivering high doses of ionising
radiation, typically across three to eight fractions with high precision and conformity. SABR …